| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
010-82848833 400-666-7788 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:NBD-556
CAS:333353-44-9
Package:25Mg,5Mg
|
|
| | NBD-556 Basic information |
| Product Name: | NBD-556 | | Synonyms: | NBD-556;N-(4-Chlorophenyl)-N'-(2,2,6,6-tetramethylpiperidin-4-yl)oxalamide;N1-(4-Chlorophenyl)-N2-(2,2,6,6-tetramethyl-4-piperidinyl)-ethanediamide;NBD-556;NBD 556; NBD556;Ethanediamide, N1-(4-chlorophenyl)-N2-(2,2,6,6-tetramethyl-4-piperidinyl)-;N1-(4-Chlorophenyl)-N2-(2,2,6,6-tetramethylpiperidin-4-yl)oxalamide;inhibit,HIV-1,fusion,virus-cell,Human immunodeficiency virus,NBD556,HIV,Inhibitor,gp120,CD4,NBD 556,NBD-556,mimetic | | CAS: | 333353-44-9 | | MF: | C17H24ClN3O2 | | MW: | 337.84 | | EINECS: | | | Product Categories: | | | Mol File: | 333353-44-9.mol |  |
| | NBD-556 Chemical Properties |
| density | 1.20 | | storage temp. | 2-8°C | | solubility | DMSO: soluble15mg/mL, clear | | form | powder | | color | white to beige |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 | | HS Code | 2933.39.9200 | | HazardClass | 6.1 | | PackingGroup | III |
| | NBD-556 Usage And Synthesis |
| Uses | NBD-556 is a N-phenyl-N''-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analog, a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120-CD4 interaction. | | Uses | NBD-556 is a N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analog, a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120-CD4 interaction. | | Biological Activity | the entry of hiv-1 into host cells is mediated by the binding of the surface subunit gp120 to the host cell receptor cd4. nbd-556 is a novel class of human immunodeficiency virus type 1 (hiv-1) entry inhibitor that block the gp120–cd4 interaction with drug-like properties. | | in vitro | a systematic study showed that nbd-556 and nbd-557 target viral entry by inhibiting the binding of hiv-1 envelope glycoprotein gp120 to the cellular receptor cd4 but did not inhibit reverse transcriptase, protease, or integrase, demonstrating that they do not target the later stages of the hiv-1 life cycle to inhibit hiv-1 infection. nbd-556 and nbd-557 were also active against hiv-1 laboratory-adapted strains including an azt-resistant strain and hiv-1 primary isolates, showing that these compounds can potentially be further modified to become potent hiv-1 entry inhibitors [1]. | | IC 50 | nbd-556 inhibited cell–cell fusion between h9/hiv-1iiib and mt-2 (ic50 ~3 μm) | | references | [1] zhao, q. , l. ma, s. jiang, h. lu, s. liu, y. he, n. strick, n. neamati, and a. k. debnath. 2005. identification of n-phenyl-n′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of hiv-1 entry inhibitors that prevent gp120 binding to cd4. virology 339:213-225. |
| | NBD-556 Preparation Products And Raw materials |
|